TY  - JOUR
AU  - Comi, Giancarlo
AU  - Alroughani, Raed
AU  - Boster, Aaron L
AU  - Bass, Ann D
AU  - Berkovich, Regina
AU  - Fernández, Óscar
AU  - Kim, Ho Jin
AU  - Limmroth, Volker
AU  - Lycke, Jan
AU  - Macdonell, Richard Al
AU  - Sharrack, Basil
AU  - Singer, Barry A
AU  - Vermersch, Patrick
AU  - Wiendl, Heinz
AU  - Ziemssen, Tjalf
AU  - Jacobs, Alan
AU  - Daizadeh, Nadia
AU  - Rodriguez, Claudio E
AU  - Traboulsee, Anthony
AU  - CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators
PY  - 2019
DO  - 10.1177/1352458519888610
UR  - http://hdl.handle.net/10668/14739
T2  - Multiple sclerosis (Houndmills, Basingstoke, England)
AB  - Alemtuzumab is given as two annual courses. Patients with continued disease activity may receive as-needed additional courses. To evaluate efficacy and safety of additional alemtuzumab courses in the CARE-MS (Comparison of Alemtuzumab and Rebif®...
LA  - en
KW  - Alemtuzumab
KW  - efficacy
KW  - multiple sclerosis
KW  - relapse
KW  - retreatment
KW  - safety
KW  - Alemtuzumab
KW  - Humans
KW  - Interferon beta-1a
KW  - Multiple Sclerosis
KW  - Multiple Sclerosis, Relapsing-Remitting
KW  - Recurrence
TI  - Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
TY  - research article
VL  - 26
ER  -